Lung Cancer

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.